Introducing Nubytide from Cenna Biosciences: a potential disease-modifying peptide that offers prevention and treatment for Alzheimer’s disease by using a unique mechanism to inhibit the production of Aß.
IND Filing 2024
Proof of Concept 2026-27
Large, growing market - $3.5B+ with 6M US patients
Differentiated technology - disease modifying
12 months from funding to first enrolled patient
Affordable, easy to administer
Strong IP position
8 issued US patents
10 issued international patents
Nubytide reduces Aß, markers of inflammation and Tau pathology
Nubytide Mission and Vision
Reduces Aß Markers
Mission: Make Nubytide available to every patient in the world suffering from Alzheimer's Disease.
Mission: Nubytide is the proactive therapy to delay or stop the onset of the disease to anyone over the age of 65.
Vision: Alzheimer Disease drugs today are monoclonal antibodies which come with higher costs, are harder to administer and are less safe.
Vision: Why Nubytide? Nubytide is a peptide drug which reduces Aß, markers of inflammation and Tau pathology.
Alzheimer's Disease is a growing global epidemic
Worldwide, at least 55 million people are believed to be living with Alzheimer's disease or other dementias.
According to the United Nations, that is more than the population of Colombia.
If breakthroughs are not discovered, this number will almost double every 20 years, reaching 78 million in 2030 and 139 million in 2050.
One in three seniors dies with Alzheimer's or related dementia.
Bright Focus Foundation – Alzheimer’s Facts and Figures
Cenna is Poised to Quickly Move Nubytide Through IND to Exit Phases
Cenna Biosciences Team
Cenna has assembled a team of seasoned biopharmaceutical specialists:
Nazneen Dewji, Ph.D.
Founder, President and CEO
Christine Smith, Ph.D.
Marwan Sabbagh, MD
Professor of Neurology
Archie W. Thurston, Jr.,
Grace Furman, Ph.D.
President and CEO,
Karlene Cork, Ph.D.
505 Coast S Blvd, Suite 407, La Jolla, CA 92037, United States